Senti Biosciences, Inc. (SNTI) fell 23.88 percent to $3.80, down $1.19 during Monday's trading, even after the company reported additional positive preliminary data from its Phase 1 trial of SENTI-202, an off-the-shelf CAR-NK cell therapy candidate for relapsed/refractory hematologic malignancies including AML.
The stock opened at $4.7600 and traded between $3.8100 and $4.9500 during the session on the Nasdaq. Volume reached 3.37 million shares, significantly higher than the average daily volume of 30,470. Senti Biosciences' 52-week range is $1.5200 to $16.9400.
The company plans to discuss the new data in a conference call and webcast scheduled for today.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.